Patient/caregiver was educated on contraindications for using Fenofibrate as follows:
- Fenofibrate is significantly metabolized in the liver. If liver function is deficient, metabolism of Fenofibrate could be slowed down. Slowing down of the drug metabolism can result in increased risk for compromised therapeutic benefits with the medication. Also, Fenofibrate has the potential to cause inflammation of liver with consequent damage to the liver function.
- Fenofibrate is significantly eliminated in urine, by the kidneys and partially in the feces. Individuals with renal disease and diminished renal function cannot eliminate Fenofibrate from their body normally, which allows the medication to be in the blood stream longer, thus increasing the risk for side-effects and toxicity with the medication.
- Fenofibrate use can significantly increase risk for gall bladder disease and formation of gall stones.
- Fenofibrate is contraindicated or carefully administered in individuals with history of gall bladder disease and gall stone formation. Fenofibrate should be administered cautiously in individuals with history of compromised liver and renal function.
